GRI.NASDAQGri Bio, INC
10-Q: GRI Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Sentiment:
Quarterly Report
GRI Bio, a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, highlighting progress in its clinical programs and recent financing activities.
Capital raiseThe company completed multiple equity offerings, raising gross proceeds of $10.5 million.The company entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares up to $10.0 million.The company entered into a securities purchase agreement to issue and sell shares and warrants for net proceeds of $3.172 million.The company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements.
Worse than expectedThe company reported a net loss of $4.137 million for the six months ended June 30, 2024, which is worse than the $8.896 million loss for the same period in 2023, but this is due to a reduction in expenses, not an increase in revenue.The company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future.
Summary
- GRI Bio reported a net loss of $2.25 million for the three months ended June 30, 2024, and a net loss of $4.137 million for the six months ended June 30, 2024.
- The company's research and development expenses were $0.877 million for the three months ended June 30, 2024, and $1.811 million for the six months ended June 30, 2024.
- General and administrative expenses were $1.38 million for the three months ended June 30, 2024, and $2.342 million for the six months ended June 30, 2024.
- As of June 30, 2024, GRI Bio had cash and cash equivalents of $6.353 million.
- The company completed multiple equity offerings, raising gross proceeds of $10.5 million, and has met the minimum stockholders equity requirement for continued listing on The Nasdaq Capital Market.
- GRI Bio expects interim data from its Phase 2a biomarker study of GRI-0621 for IPF in the fourth quarter of 2024 and topline results in the first quarter of 2025.
- The company is also developing GRI-0803 for autoimmune disorders, with initial focus on lupus, and expects to file an IND for a Phase 1a/1b trial in 2025.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While the company has made progress in its clinical programs and secured necessary funding, it continues to operate at a loss and faces significant financial risks. The going concern warning and reliance on future capital raises temper the positive aspects.
Positives
- The company successfully raised $10.5 million through multiple equity offerings, addressing Nasdaq's minimum stockholders' equity requirement.
- GRI Bio has made progress in its clinical program for GRI-0621, with a Phase 2a biomarker study underway and interim data expected in the fourth quarter of 2024.
- The company has received authorization to initiate the Phase 2a biomarker study in the United Kingdom.
- The company is advancing its GRI-0803 program for autoimmune disorders, with plans to file an IND in 2025.
- The company has reduced general and administrative expenses compared to the same period last year.
Negatives
- GRI Bio continues to incur net losses, with a loss of $2.25 million for the three months ended June 30, 2024, and $4.137 million for the six months ended June 30, 2024.
- The company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future.
- There is substantial doubt about the company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.
- The company is dependent on raising additional capital to fund its business activities.
Risks
- The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
- There is no assurance that additional financing will be available when needed.
- If the company is unable to obtain additional financing, it may be forced to reduce or discontinue its operations.
- The company is subject to the risk of delisting from Nasdaq if the share price falls below $1.00 for 30 trading days.
- The company is still in the early stages of clinical development and faces the risk of clinical trial failure.
Future Outlook
The company expects interim data from its Phase 2a biomarker study of GRI-0621 for IPF in the fourth quarter of 2024 and topline results in the first quarter of 2025. The company also plans to file an IND for a Phase 1a/1b trial of GRI-0803 for autoimmune disorders, initially targeting lupus, in 2025.
Management Comments
- Based on our current enrollment projections, we now expect interim data from this trial to be available in the fourth quarter of 2024 and topline results to be available in the first quarter of 2025.
- We expect to file an IND with respect to this Phase 1a and 1b trial in 2025.
Industry Context
GRI Bio is operating in the competitive biopharmaceutical industry, focusing on innovative therapies for inflammatory, fibrotic, and autoimmune disorders. The company's lead product candidate, GRI-0621, targets IPF, a disease with limited treatment options, while GRI-0803 aims to address autoimmune disorders like lupus, where new treatments are needed. The company's progress is being closely watched by investors and competitors in the space.
Comparison to Industry Standards
- GRI Bio's cash position of $6.353 million is relatively low compared to other clinical-stage biopharmaceutical companies, which often require significant capital to fund clinical trials.
- The company's net losses are typical for a company at this stage of development, as they are investing heavily in research and development.
- The company's focus on IPF and autoimmune disorders aligns with current industry trends, as these areas have significant unmet medical needs.
- The company's reliance on equity financing is common for early-stage biopharmaceutical companies, but it also carries the risk of dilution for existing shareholders.
- Compared to companies like Boehringer Ingelheim and Roche, which have approved therapies for IPF, GRI Bio is still in the early stages of clinical development, but its approach of targeting iNKT cells is novel and could offer a differentiated treatment option.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Former Chief Executive Officer | David Baker | NA | 2023-04-21 | Resignation pursuant to the Merger |
Legal Proceedings
- The company is not currently a party to any material legal proceedings.
Stakeholder Impact
- Shareholders face the risk of dilution from future equity offerings.
- Employees are subject to the risk of potential layoffs if the company is unable to secure additional funding.
- Patients with IPF and autoimmune disorders may benefit from the company's development of new therapies.
- Creditors face the risk of non-payment if the company is unable to continue as a going concern.
Next Steps
- The company plans to continue enrollment in its Phase 2a biomarker study of GRI-0621 for IPF.
- The company expects to release interim data from the Phase 2a study in the fourth quarter of 2024 and topline results in the first quarter of 2025.
- The company intends to file an IND for a Phase 1a/1b trial of GRI-0803 for autoimmune disorders in 2025.
- The company will continue to seek additional funding to support its operations and development programs.
Key Dates
| Date | Description |
|---|---|
| 2022-12-13 | Date of the initial Merger Agreement and Bridge Securities Purchase Agreement. |
| 2022-12-14 | First closing of the Bridge Notes. |
| 2023-02-17 | Amendment to the Merger Agreement. |
| 2023-03-09 | Second closing of the Bridge Notes. |
| 2023-04-21 | Date of the Merger with Vallon Pharmaceuticals, Inc. |
| 2023-05-08 | Escrow agent disbursed shares to Altium. |
| 2023-11-22 | Nasdaq notification of non-compliance with minimum stockholders equity requirement. |
| 2024-01-05 | Nasdaq notification of non-compliance with minimum bid price rule. |
| 2024-01-29 | Effective date of the one-for-seven reverse stock split. |
| 2024-02-01 | Date of the February 2024 Securities Purchase Agreement. |
| 2024-02-06 | Date of issuance of Series B warrants. |
| 2024-03-01 | Authorization of clinical trial application from the UK. |
| 2024-05-20 | Date of the At The Market Offering Agreement with H.C. Wainwright & Co., LLC. |
| 2024-06-07 | Stockholders approved a one-for-thirteen reverse stock split. |
| 2024-06-17 | Effective date of the one-for-thirteen reverse stock split. |
| 2024-06-26 | Date of the June 2024 Securities Purchase Agreement. |
| 2024-07-02 | Nasdaq notified the company that the stockholders equity deficiency had been cured. |
| 2024-07-19 | Nasdaq notified the company that it was in compliance with the Minimum Bid Price Rule. |
| 2024-07-26 | Filing of prospectus supplement to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement. |
| 2024-08-06 | Date of outstanding shares of the Registrants common stock. |
| 2024-08-13 | Date of the report. |
Keywords
GRI Bio, biopharmaceutical, clinical-stage, GRI-0621, idiopathic pulmonary fibrosis, IPF, GRI-0803, autoimmune disorders, lupus, financing, equity offering, Nasdaq, reverse stock split, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.